ROBOSENSE
3.1.2020 15:02:09 CET | Business Wire | Press release
RoboSense , the world’s leading autonomous driving LiDAR perception solution provider , announced today that the solid-state LiDAR RS-LiDAR-M1Simple(Simple Sensor Version ) is now ready for customer delivery, priced at $1,898 . The new RS-LiDAR-M1Simple is less than half the size of the previous version, with dimensions of 4.3” x 1.9” x 4.7” (110mm x 50mm x 120mm), and is equipped with enhanced hardware performance virtually equal to the serial production version provided to OEMs. The main body design of this automotive-grade solid-state LiDAR is finalized and ready for shipment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200103005139/en/
In addition, RoboSense will demonstrate the world’s first smart solid-state LiDAR, the RS-LiDAR-M1Smart (Smart Sensor Version), at CES 2020 in Las Vegas, Booth 6138, LVCC North Hall from Jan 7-10, 2020 with an on-vehicle public road test. The RS-LiDAR-M1Smart main body is embedded with an AI perception algorithm that fully takes advantage of LiDAR’s potential to transform conventional 3D LiDAR sensors to a full data analysis and comprehension system.
“The RS-LiDAR-M1 is an optimal choice for the serial production of self-driving cars, far superior to mechanical LiDAR. The sooner solid-state LiDAR is used, the sooner production will be accelerated to mass-market levels,” said Mark Qiu, RoboSense COO.
RS-LiDAR-M1 Family Features:
- 125 laser beams with exceptional performance: the RS-LiDAR-M1 has a field of view of 120°*25°, which is the MEMS solid-state LiDAR’s largest field of view among released products worldwide. RoboSense uses 905nm lasers with low cost, automotive grade and small size instead of expensive 1550nm lasers. At the same time, RoboSense continuously breaks ranging ability limits to 150m at 10% NIST target, which is also MEMS solid-state LiDAR’s longest detection range.
- World’s smallest MEMS solid-state LiDAR: one-tenth the size of conventional 64-beam mechanical LiDAR. The RS-LiDAR-M1 can be easily embedded in the car’s body while still maintaining the vehicle’s appearance intact.
- Reduced parts from hundreds to dozens in comparison to traditional mechanical LiDARs for lower cost, shorter production time, and large-scale production capacity .
- Modular design: the scalability and layout flexibility of the optical module lay the foundation for subsequent MEMS LiDAR products and support the customization of products for different application cases.
- Stable and reliable: RoboSense fully implemented IATF16949 quality management system and ISO26262 functional safety standards, combining ISO16750 test requirement and other automotive-grade reliability specifications to verify the RS-LiDAR-M1 series of products.
- All-weather: In Vienna, Austria, the RS-LiDAR-M1 was tested for rain and fog under different light and wind speed conditions. The test results prove that the RS-LiDAR-M1 has met the standards, and the final mass-produced RS-LiDAR-M1 will adapt to all climatic and working conditions.
- Minimal wear and tear: as a solid-state LiDAR, the RS-LiDAR-M1 eliminates potential optoelectronic device failures due to mechanical rotation.
The RS-LiDAR-M1Smart is a comprehensive system with sensor hardware, AI point cloud algorithm, and chipsets, which provides an end-to-end customer environment perception solution. RoboSense’s powerful AI perception algorithm injects the sensor with structured semantic-level comprehensive information, focusing on the perception of moving objects.
For orders visit www.robosense.ai/buy or to contact a RoboSense account manager.
About RoboSense
The world’s leading autonomous driving LiDAR perception solution provider. RoboSense technologies are widely used in autonomous driving logistics vehicles, buses, and passenger cars, with partners including SAIC, BAIC, Baidu, Cainiao Network, JD.com, Samsung, ControlWorks, Aidrivers, and more. For more information, see the website at: http://www.robosense.ai .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200103005139/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom